KRYSKrystal Biotech, Inc.

Ticker: KRYS | Filing: 10-Q | Filed: November 2, 2026 | Current Price: $286.61 | Today's Change: -13.75%

---

What Happened

Krystal Biotech, Inc. filed its quarterly report on Form 10-Q with the SEC on November 2, 2026, covering the third quarter of fiscal year 2026. The company reported revenue of $282.0 million for Q3 FY2026, alongside operating income of $117.0 million — figures that reflect a commercial-stage biopharma generating meaningful profitability from its operations. Net income for the quarter came in at $35.7 million, with diluted earnings per share of $5.14 and basic EPS of $5.31.

---

Why It Matters

The headline numbers show a company with strong top-line revenue and robust operating income, but a notable gap between operating income ($117.0M) and net income ($35.7M) will likely draw investor scrutiny — implying significant below-the-line charges, taxes, or other items that substantially reduced what flowed to the bottom line. For a stock trading near $286 and down sharply on the day, the divergence between operating-level performance and reported net income is almost certainly at the center of the market's reaction. Investors will want to understand the composition of those below-the-line items before drawing conclusions about underlying earnings quality.

Key figures at a glance:

• Revenue: $282.0M (Q3 FY2026)
• Operating Income: $117.0M (Q3 FY2026)
• Net Income: $35.7M (Q3 FY2026)
• Basic EPS: $5.31
• Diluted EPS: $5.14

---

Analysis

At $282 million in quarterly revenue, Krystal Biotech continues to demonstrate that its commercial launch — anchored by its gene therapy platform — is generating substantial scale. Operating income of $117 million implies an operating margin of roughly 41%, which is an impressive benchmark for any biopharma at this stage of commercialization.

However, the sharp contrast between operating income and net income is the headline risk here. The gap of approximately $81 million between the two lines — not explained in the structured data provided — suggests material non-operating items. These could include items such as tax provisions, interest expense, fair-value adjustments on instruments, or one-time charges. Until those details are fully digested by the market, volatility is likely to persist.

The stock's 13.75% decline today suggests the market may be reading something in the full filing beyond what the top-line revenue and operating income figures alone would imply. Investors following this story — including those aware of StockWatch's existing initiating coverage — will want to scrutinize the detailed income statement and any management commentary on guidance adjustments or pipeline developments disclosed in this 10-Q.

What to watch next:

• The breakdown of items between operating income and net income in the full filing
• Any changes to full-year revenue or margin guidance embedded in management discussion
• Pipeline or regulatory updates that may have accompanied this quarterly filing

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Krystal Biotech's SEC filing and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research recommendation. No rating or price target is issued or implied herein. Readers should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Existing Coverage

StockWatch has full coverage on KRYS, published 2026-09-04. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-02. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm